Clinical trial
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 21, 2018
- Completion date
- October 24, 2026
- Enrollment
- 54 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
alk-positive large b-cell lymphoma, diffuse large b-cell lymphoma activated b-cell type, diffuse large b-cell lymphoma associated with chronic inflammation, diffuse large b-cell lymphoma germinal center b-cell type, diffuse large b-cell lymphoma, not otherwise specified, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, ebv-positive mucocutaneous ulcer, hhv8-positive diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, intravascular large b-cell lymphoma, large b-cell lymphoma with 11q aberration, large b-cell lymphoma with irf4 rearrangement, plasmablastic lymphoma, primary diffuse large b-cell lymphoma of the central nervous system, primary effusion lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent gray-zone lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent lymphomatoid granulomatosis, recurrent primary cutaneous diffuse large b-cell lymphoma, leg type, recurrent primary mediastinal large b-cell lymphoma, recurrent t-cell/histiocyte-rich large b-cell lymphoma, refractory b-cell non-hodgkin lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory gray-zone lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory primary cutaneous diffuse large b-cell lymphoma, leg type, refractory primary mediastinal large b-cell lymphoma, refractory t-cell/histiocyte-rich large b-cell lymphoma